Daphne Karydas
2020
In 2020, Daphne Karydas earned a total compensation of $3.1M as Chief Financial Officer at Syndax Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $80,750 |
|---|---|
| Option Awards | $2,847,733 |
| Salary | $200,881 |
| Total | $3,129,364 |
Karydas received $2.8M in option awards, accounting for 91% of the total pay in 2020.
Karydas also received $80.8K in non-equity incentive plan and $200.9K in salary.
Rankings
In 2020, Daphne Karydas' compensation ranked 3,716th out of 13,090 executives tracked by ExecPay. In other words, Karydas earned more than 71.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,716 out of 13,090 | 72nd |
Division Manufacturing | 1,466 out of 5,620 | 74th |
Major group Chemicals And Allied Products | 552 out of 2,253 | 76th |
Industry group Drugs | 478 out of 1,953 | 76th |
Industry Pharmaceutical Preparations | 361 out of 1,458 | 75th |
Source: SEC filing on April 1, 2021.
Karydas' colleagues
We found two more compensation records of executives who worked with Daphne Karydas at Syndax Pharmaceuticals in 2020.